Melanocortin control of cell trafficking in vascular inflammation

Advances in Experimental Medicine and Biology

Volumn 681, Issue , 2010, Pages 88-106

  Patel, Hetal B ^b   Leoni, Giovanna ^b   Melendez, Trinidad Montero ^b   Sampaio, André L F ^b   Perretti, Mauro ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; AP 214; BMS 470539; CORTICOTROPIN; CYCLIC AMP; GAMMA INTERFERON; HP 228; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERMEDIN; LIPOPOLYSACCHARIDE; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MELATONIN 2 RECEPTOR; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ASTHMA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL MIGRATION; COLITIS; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; DUODENUM INJURY; ENDOTHELIUM CELL; ENDOTOXEMIA; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; GOUT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEPATITIS; HORMONAL REGULATION; HORMONE ACTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; KIDNEY INJURY; KIDNEY ISCHEMIA; MACROPHAGE; MAST CELL; MICROCIRCULATION; MONOCYTE; NEUTROPHIL; NONHUMAN; OBESITY; PAIN; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SKIN DISEASE; TREATMENT OUTCOME; VASCULITIS;

AMINO ACID SEQUENCE; ANIMALS; DRUG DISCOVERY; HUMANS; INFLAMMATION; MELANOCORTINS; MICROCIRCULATION; VASCULAR DISEASES;

EID: 79959550580     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6354-3_7     Document Type: Article

References (94)

1. Hart F. Corticosteroid therapy in the rheumatic disorders. In: Huskisson E, ed. Anti-rheumatic drugs New York: Praeger, 1983;497-508.
2. Hench PS, Kendall EC, Slocumb CH et al. The effect of the adrenal cortex (17-hydroxy-11-dehydrocortisone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary report. Proc Staff Meet Mayo Clin 1949; 24:181-197.
3. Dougherty TF, White A. Influence of hormones on lymphoid tissue structure and function. The role of the pituitary adrenotrophic hormone in the regulation of the lymphocytes and other cellular elements of the blood. Endocrinology 1944; 35:1-14.
4. Gutman AB, Yu TF. Effects of ACTH in gout. Am J Med 1950; 9:24-30.
5. Saunders RH, Adams E. Changes in circulating leukocytes following administration of adrenal cortex extract and adrenocorticotropic hormone (ACTH) in infectious mononucleosis and chronic lymphatic leukaemia. Blood 1950; 5:732-738.
6. Ritter J, Kerr LD, Valeriano-Marcet J et al. ACTH revisited: Effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21:696-699. (Pubitemid 24126767)
7. Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs 2008; 68:407-415. (Pubitemid 351342012)
8. Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab 2003; 284:E468-474. (Pubitemid 36237533)
9. Ley K, Laudanna C, Cybulsky MI et al. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678-689. (Pubitemid 47327397)
10. Nathan C. Points of control in inflammation. Nature 2002; 420:846-852. (Pubitemid 36019637)
11. Nathan C. Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 2006; 6:173-182. (Pubitemid 43290987)
12. Choi EY et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 2008; 322:1101-1104.
13. Perretti M. Endogenous mediators that inhibit the leukocyte-endothelium interaction. Trends in Pharmacological Sciences 1997; 18:418-425. (Pubitemid 27521059)
14. Serhan CN et al. Resolution of inflammation: State of the art, definitions and terms. FASEB J 2007; 21:325-332. (Pubitemid 46213480)
15. Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol 2005; 6:1191-1197. (Pubitemid 43045627)
16. Kubes P, Granger DN. Leukocyte-endothelial cell interactions evoked by mast cells. Cardiovasc Res 1996; 32:699-708. (Pubitemid 26332309)
17. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5:953-964. (Pubitemid 41746764)
18. Getting SJ. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006; 111:1-15. (Pubitemid 43765537)
19. Catania A, Gatti S, Colombo G et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56:1-29. (Pubitemid 38314578)
20. Lipton JM. Modulation of host defense by the neuropeptide alpha-MSH. Yale J Biol Med 1990; 63:173-182. (Pubitemid 20342086)
21. Lipton JM, Macaluso A, Hiltz ME et al. Central administration of the peptide alpha-MSH inhibits inflammation in the skin. Peptides 1991; 12:795-798.
22. Chiao H et al. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997; 99:1165-1172. (Pubitemid 27142751)
23. Gatti S et al. Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions. J Surg Res 2006; 131:209-214.
24. Kang L et al. A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide- induced cytokine accumulation and leukocyte infiltration in mice. J Leukoc Biol 2006; 80:897-904. (Pubitemid 44835908)
25. Ceriani G et al. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation 1994; 1:28-32.
26. Manna SK, Aggarwal BB. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 1998; 161:2873-2880. (Pubitemid 28425709)
27. Ichiyama T et al. Alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation. Exp Neurol 1999; 157:359-365. (Pubitemid 29260743)
28. Lipton JM et al. Mechanisms of antiinflammatory action of alpha-MSH peptides. In vivo and in vitro evidence. Ann N Y Acad Sci 1999; 885:173-182.
29. Chiao H et al. Alpha-melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation. J Clin Invest 1996; 97:2038-2044. (Pubitemid 26143957)
30. Gatti S et al. Alpha-melanocyte-stimulating hormone protects the allograft in experimental heart transplantation. Transplantation 2002; 74:1678-1684. (Pubitemid 36019317)
31. Leoni G et al. Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. FASEB J 2008; 22:4228-4238.
32. Catania A, Airaghi L, Colombo G et al. Alpha-melanocyte-stimulating hormone in normal human physiology and disease states. Trends Endocrinol Metab 2000; 11:304-308.
33. Bilenko MV. Ischemia and Reperfusion of Various Organs: Injury Mechanisms, Methods of Prevention and Treatment Nova Science Publishers, 2000.
34. Bazzani C et al. Protective effect of melanocortin peptides in rat myocardial ischemia. J Pharmacol Exp Ther 2001; 297:1082-1087. (Pubitemid 32472507)
35. Getting SJ et al. MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct. J Leukoc Biol 2004; 76:845-853. (Pubitemid 39313721)
36. Chiao H et al. Alpha-melanocyte-stimulating hormone inhibits renal injury in the absence of neutrophils. Kidney Int 1998; 54:765-774. (Pubitemid 28397394)
37. Lee YS, Park JJ, Chung KY. Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury. Transplant Proc 2008; 40:2142-2144.
38. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35. (Pubitemid 37328697)
39. Star RA et al. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocytestimulating hormone. Proc Natl Acad Sci USA 1995; 92:8016-8020.
40. Blalock JE. Proopiomelanocortin-derived peptides in the immune system. Clinical Endocrinology 1985; 22:823-827.
41. Getting SJ et al. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release and inhibit neutrophil migration in acute experimental inflammation. J Immunol 1999; 162:7446-7453. (Pubitemid 29277724)
42. Lam CW, Getting SJ, Perretti M. In vitro and in vivo induction of heme oxygenase 1 in mouse macrophages following melanocortin receptor activation. J Immunol 2005; 174:2297-2304. (Pubitemid 40223978)
43. Getting SJ et al. [D-Trp8]-gamma-melanocyte-stimulating hormone exhibits anti-inflammatory efficacy in mice bearing a nonfunctional MC1R (recessive yellow e/e mouse). Mol Pharmacol 2006; 70:1850-1855. (Pubitemid 44771900)
44. Getting SJ, Allcock GH, Flower R et al. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J Leukoc Biol 2001; 69:98-104. (Pubitemid 32095123)
45. Taherzadeh S et al. Alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages. Am J Physiol 1999; 276:R1289-1294. (Pubitemid 29249650)
46. Bhardwaj R et al. Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J Immunol 1997; 158:3378-3384. (Pubitemid 127484057)
47. Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/ interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: Evidence for dual mechanisms of action. Biochem Pharmacol 2001; 61:613-621. (Pubitemid 32178496)
48. Woolley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003; 348:1709-1711. (Pubitemid 36459479)
49. Galli SJ et al. Mast cells as "tunable" effector and immunoregulatory cells: Recent advances. Annu Rev Immunol 2005; 23:749-786. (Pubitemid 40563184)
50. Adachi S, Nakano T, Vliagoftis H et al. Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. J Immunol 1999; 163:3363-3368. (Pubitemid 29431838)
51. Artuc M et al. Human mast cells in the neurohormonal network: Expression of POMC, detection of precursor proteases and evidence for IgE-dependent secretion of alpha-MSH. J Invest Dermatol 2006; 126:1976-1981.
52. Oliani SM et al. Fluctuation of annexin-A1 positive mast cells in chronic granulomatous inflammation. Inflamm Res 2008; 57:450-456.
53. Getting SJ, Di Filippo C, D'Amico M et al. The melanocortin peptide HP228 displays protective effects in acute models of inflammation and organ damage. Eur J Pharmacol 2006; 532:138-144.
54. Getting SJ et al. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J 2006; 20:2234-2241. (Pubitemid 44953853)
55. Manna SK, Sarkar A, Sreenivasan Y. Alpha-melanocyte-stimulating hormone down-regulates CXC receptors through activation of neutrophil elastase. Eur J Immunol 2006; 36:754-769.
56. Capsoni F et al. The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils. Peptides 2007; 28:2016-2022. (Pubitemid 47432811)
57. Oktar BK, Yuksel M, Alican I. The role of cyclooxygenase inhibition in the effect of alpha-melanocytestimulating hormone on reactive oxygen species production by rat peritoneal neutrophils. Prostaglandins Leukot Essent Fatty Acids 2004; 71:1-5. (Pubitemid 38881238)
58. Hartmeyer M et al. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J Immunol 1997; 159:1930-1937. (Pubitemid 127484182)
59. Scholzen TE et al. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 2003; 144:360-370. (Pubitemid 36076126)
60. Hill RP, MacNeil S, Haycock JW. Melanocyte stimulating hormone peptides inhibit TNF-alpha signaling in human dermal fibroblast cells. Peptides 2006; 27:421-430. (Pubitemid 43162914)
61. Becher E et al. Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R. Ann N Y Acad Sci 1999; 885:188-195.
62. Brzoska T et al. Alpha-melanocyte-stimulating hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects in vitro and in vivo and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008; 29:581-602.
63. Cooper A et al. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 2005; 175:4806-4813. (Pubitemid 41362024)
64. Robbins LS et al. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 1993; 72:827-834. (Pubitemid 23110225)
65. Chen AS et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26:97-102.
66. Maaser C et al. Crucial role of the melanocortin receptor MC1R in experimental colitis. Gut 2006; 55:1415-1422. (Pubitemid 44476784)
67. Getting SJ et al. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: Studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. J Immunol 2003; 170:3323-3330. (Pubitemid 36302211)
68. Getting SJ et al. A role for MC3R in modulating lung inflammation. Pulm Pharmacol Ther 2008; 21:866-873.
69. Raap U et al. Alpha-melanocyte-stimulating hormone inhibits allergic airway inflammation. J Immunol 2003; 171:353-359. (Pubitemid 36745308)
70. Huszar D et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88:131-141. (Pubitemid 27180337)
71. Butler AA et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000; 141:3518-3521. (Pubitemid 32269044)
72. Ellacott KL, Murphy JG, Marks DL et al. Obesity-induced inflammation in white adipose tissue is attenuated by loss of melanocortin-3 receptor signaling. Endocrinology 2007; 148:6186-6194. (Pubitemid 350146148)
73. Chen W et al. Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997; 91:789-798. (Pubitemid 28007735)
74. Taylor AW, Kitaichi N, Biros D. Melanocortin 5 receptor and ocular immunity. Cell Mol Biol (Noisy-le-grand) 2006; 52:53-59. (Pubitemid 43989248)
75. Matsubara M, Albone E, Gorman JH et al. Alpha-melanocyte stimulating hormone fused transferrin: A novel adjunct to reperfusion therapy for acute MI. Journal of Cardiac Failure 2007; 13:S92.
76. Giuliani D et al. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology 2006; 147:1126-1135. (Pubitemid 43244343)
77. Kelly JM et al. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides 2006; 27:431-437. (Pubitemid 43162915)
78. 2 tetrapeptides at the melanocortin receptors. Eur J Pharmacol 2003; 462:41-52. (Pubitemid 36183733)
79. Todorovic A et al. N-terminal fatty acylated His-dPhe-Arg-Trp-NH(2) tetrapeptides: Influence of fatty acid chain length on potency and selectivity at the mouse melanocortin receptors and human melanocytes. J Med Chem 2005; 48:3328-3336. (Pubitemid 40628051)
80. Doi K et al. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008; 73:1266-1274. (Pubitemid 351693164)
81. Fan W et al. Role of melanocortinergic neurones in feeding and the agouti obesity syndrome. Nature 1997; 385:165-168. (Pubitemid 27034218)
82. Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 2003; 306:631-637. (Pubitemid 36886162)
83. Grieco P et al. Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. Biochem Biophys Res Commun 2002; 292:1075-1080. (Pubitemid 34692604)
84. Grieco P et al. Extensive structure-activity studies of lactam derivatives of MT-II, SHU-9119: Their activity and selectivity at human melanocortin receptors 3, 4 and 5. J Pept Res 2003; 62:199-206. (Pubitemid 37338830)
85. Grieco P et al. D-Amino acid scan of gamma-melanocyte-stimulating hormone: Importance of Trp(8) on human MC3 receptor selectivity. J Med Chem 2000; 43:4998-5002. (Pubitemid 32040975)
86. Mayorov AV et al. Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem 2006; 49:1946-1952.
87. Herpin TF et al. Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. J Med Chem 2003; 46:1123-1126. (Pubitemid 36428217)
88. Skottner A et al. Anti-inflammatory potential of melanocortin receptor-directed drugs. Ann N Y Acad Sci 2003; 994:84-89. (Pubitemid 36793853)
89. Sharma HS et al. Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors. J Neural Transm 2006; 113:463-476.
90. Chuang IC et al. Intramuscular electroporation with the pro-opiomelanocortin gene in rat adjuvant arthritis. Arthritis Res Ther 2004; 6:R7-R14.
91. Getting SJ, Christian HC, Flower RJ et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002; 46:2765-2775. (Pubitemid 36118942)
92. Schulte-Herbruggen O et al. Alpha-MSH promotes spontaneous post-ischemic pneumonia in mice via melanocortin-receptor-1. Exp Neurol 2008; 210:731-739.
93. Deng J, Hu X, Yuen PS et al. Alpha-melanocyte-stimulating hormone inhibits lung injury after renal ischemia/reperfusion. Am J Respir Crit Care Med 2004; 169:749-756. (Pubitemid 38338928)
94. Ottani A et al. Vagus nerve mediates the protective effects of melanocortins against cerebral and systemic damage after ischemic stroke. J Cereb Blood Flow Metab 2008.